724 related articles for article (PubMed ID: 16205964)
21. Immunohistochemical Analysis of PDGFR-α, PDGFR-β and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
Sanft DM; Worme MD; Rielo de Moura L; Zoroquiain P; Fernandes BF; Antecka E; Burnier MN
Ophthalmic Res; 2016; 55(3):159-62. PubMed ID: 26761215
[TBL] [Abstract][Full Text] [Related]
22. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
[TBL] [Abstract][Full Text] [Related]
23. Role of KIT and platelet-derived growth factor receptors as oncoproteins.
Fletcher JA
Semin Oncol; 2004 Apr; 31(2 Suppl 6):4-11. PubMed ID: 15175998
[TBL] [Abstract][Full Text] [Related]
24. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
[TBL] [Abstract][Full Text] [Related]
26. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
27. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2008 Jan; 108(1):182-90. PubMed ID: 18028988
[TBL] [Abstract][Full Text] [Related]
28. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
29. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
30. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
[TBL] [Abstract][Full Text] [Related]
32. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
33. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Demetri GD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Cristofanilli M; Morandi P; Krishnamurthy S; Reuben JM; Lee BN; Francis D; Booser DJ; Green MC; Arun BK; Pusztai L; Lopez A; Islam R; Valero V; Hortobagyi GN
Ann Oncol; 2008 Oct; 19(10):1713-9. PubMed ID: 18515258
[TBL] [Abstract][Full Text] [Related]
35. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
36. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
37. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571).
Holcombe RF; Gu M; Imagawa D; Milovanovic T
Anticancer Drugs; 2003 Sep; 14(8):651-7. PubMed ID: 14501388
[TBL] [Abstract][Full Text] [Related]
38. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
39. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
Knight GW; McLellan D
Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]